First QUARTER JANUARY - MARCH- Consolidated net sales amounted to
SEK 222.6 (205.7) million, an increase of 8% -
Consolidated EBITDA amounted to
SEK 40.5 (31.4) million, an increase of 29% -
EBITDA margin amounted to 18 (15) per cent
-
Earnings after tax from continuing operations amounted to
SEK 15.1 (10.4) million -
Earnings per share amounted to
SEK 0.9 (0.7) -
Cash flow from operations amounted to
SEK 17.3 (27.8) million
Message from the CEO
Overall the first quarter showed good demand in most of the market segments where the group's companies operate. Total sales increased by 8% and EBITDA by 29%.
The pandemic continued to cause challenges and uncertainty for the operations. For the manufacturing sites, where remote work isn't possible, it is still a priority to reduce the risk of spread of infection.
Supply disruptions have been noted in several companies during the first quarter, but these have so far been managed without affecting sales. Component shortages and transportation can present a challenge going forward and are closely monitored by the companies.
The
The segment's EBITDA increased significantly. Strong margins in Abilia and profitability improvement in Inpac contributed to the result and the strong margin for the segment.
Cardiolex continued to deliver and integration of the Nordic and German ECG product portfolio progressed. It was also reassuring to see that Multi-Ply's order intake improved during the first quarter and demonstrated clear signs of recovery after the weaker fourth quarter and start of the year.
The specialty pharma segment increased profit despite a decline in sales in the first quarter. Demand in the segment continues to be impacted by the pandemic, which affects product mix, volumes and predictability.
Profit increased in the first quarter primarily due to improved results in
In conclusion, the group delivered a strong first quarter and there is a lot of energy to tackle challenges and to develop ample opportunities in our companies.
This disclosure contains information that
For more information, contact:
Q1 presentation in english is available on the company's website
About
https://news.cision.com/medcap-ab/r/ebitda-increased-by-29--in-the-first-quarter,c3342491
(c) 2021 Cision. All rights reserved., source